See more : China Vanke Co., Ltd. (000002.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Mallinckrodt plc (MNK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mallinckrodt plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Narryer Metals Limited (NYM.AX) Income Statement Analysis – Financial Results
- DraftKings Inc. (0ABA.L) Income Statement Analysis – Financial Results
- Concentra Group Holdings Parent, Inc. (CON) Income Statement Analysis – Financial Results
- Absolute Clean Energy Public Company Limited (ACE.BK) Income Statement Analysis – Financial Results
- Industrial Tech Acquisitions II, Inc. (ITAQW) Income Statement Analysis – Financial Results
Mallinckrodt plc (MNK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mallinckrodt.com
About Mallinckrodt plc
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21B | 2.21B | 2.21B | 3.16B | 3.22B | 3.22B | 3.38B | 3.35B | 2.54B | 2.21B | 2.06B | 2.02B |
| Cost of Revenue | 1.32B | 1.32B | 1.54B | 1.74B | 1.74B | 1.57B | 1.53B | 1.49B | 1.34B | 1.18B | 1.09B | 1.11B |
| Gross Profit | 891.70M | 891.70M | 669.40M | 1.42B | 1.47B | 1.66B | 1.86B | 1.85B | 1.20B | 1.03B | 964.80M | 914.90M |
| Gross Profit Ratio | 40.37% | 40.37% | 30.24% | 44.95% | 45.75% | 51.41% | 54.87% | 55.38% | 47.36% | 46.62% | 46.92% | 45.25% |
| Research & Development | 205.20M | 205.20M | 290.80M | 349.40M | 361.10M | 277.30M | 262.20M | 185.10M | 166.90M | 166.50M | 144.10M | 141.50M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 581.80M | 581.80M | 884.10M | 831.00M | 834.10M | 920.90M | 925.30M | 1.17B | 842.10M | 611.40M | 551.70M | 532.50M |
| Other Expenses | 0.00 | 22.00M | 7.40M | 63.60M | 30.90M | 6.00M | -600.00K | 8.10M | 1.80M | 800.00K | 1.00M | 2.90M |
| Operating Expenses | 787.00M | 787.00M | 1.17B | 1.18B | 1.20B | 1.20B | 1.19B | 1.35B | 1.01B | 777.90M | 695.80M | 674.00M |
| Cost & Expenses | 2.10B | 2.10B | 2.72B | 2.92B | 2.94B | 2.76B | 2.71B | 2.85B | 2.35B | 1.96B | 1.79B | 1.78B |
| Interest Income | 1.90M | 1.90M | 5.90M | 9.50M | 8.20M | 4.60M | 1.30M | 1.00M | 1.50M | 300.00K | 400.00K | 200.00K |
| Interest Expense | -222.60M | 222.60M | 261.10M | 309.00M | 370.20M | 369.10M | 384.60M | 255.60M | 82.60M | 19.50M | 500.00K | 600.00K |
| Depreciation & Amortization | 328.90M | 675.80M | 885.20M | 951.10M | 852.10M | 808.30M | 834.50M | 672.50M | 275.90M | 139.60M | 130.90M | 119.80M |
| EBITDA | -723.50M | 804.40M | 393.00M | 1.27B | 1.17B | 468.70M | 1.50B | 1.18B | 473.30M | 254.30M | 401.30M | 363.80M |
| EBITDA Ratio | -32.76% | 36.42% | 17.76% | 40.01% | 36.30% | 14.55% | 44.45% | 35.27% | 18.63% | 11.50% | 19.52% | 17.99% |
| Operating Income | -1.05B | 128.60M | -492.20M | 314.10M | -3.72B | 420.10M | 617.30M | 461.80M | -284.10M | 148.70M | 235.20M | 240.70M |
| Operating Income Ratio | -47.65% | 5.82% | -22.24% | 9.93% | -115.71% | 13.04% | 18.26% | 13.80% | -11.18% | 6.72% | 11.44% | 11.91% |
| Total Other Income/Expenses | 222.60M | -958.40M | -468.60M | -1.91B | -331.10M | -358.50M | -383.90M | -246.50M | -79.30M | -18.40M | 900.00K | 2.50M |
| Income Before Tax | -829.80M | -829.80M | -960.80M | -1.59B | -4.05B | 61.60M | 233.40M | 215.30M | -363.40M | 130.30M | 236.10M | 243.20M |
| Income Before Tax Ratio | -37.57% | -37.57% | -43.41% | -50.32% | -126.01% | 1.91% | 6.90% | 6.43% | -14.30% | 5.89% | 11.48% | 12.03% |
| Income Tax Expense | -112.40M | -106.30M | 8.90M | -584.30M | -430.10M | -1.71B | -255.60M | -92.90M | -44.80M | 70.20M | 94.80M | 86.20M |
| Net Income | -717.40M | -723.50M | -969.70M | -1.01B | -3.61B | 2.13B | 643.70M | 324.70M | -319.30M | 61.10M | 134.60M | 150.70M |
| Net Income Ratio | -32.48% | -32.76% | -43.81% | -31.85% | -112.17% | 66.25% | 19.04% | 9.70% | -12.57% | 2.76% | 6.55% | 7.45% |
| EPS | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.85 | 5.82 | 2.78 | -4.92 | 1.06 | 2.33 | 2.61 |
| EPS Diluted | -8.47 | -8.54 | -11.48 | -12.00 | -42.94 | 21.80 | 5.77 | 2.75 | -4.92 | 1.06 | 2.33 | 2.61 |
| Weighted Avg Shares Out | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.70M | 110.60M | 115.80M | 64.90M | 57.70M | 57.70M | 57.70M |
| Weighted Avg Shares Out (Dil) | 84.70M | 84.70M | 84.50M | 83.90M | 84.00M | 97.90M | 111.50M | 117.20M | 64.90M | 57.80M | 57.70M | 57.70M |
Will an Opioid Manufacturer Stage a Comeback With This New Venture?
Mallinckrodt (NYSE:MNK) Shares Gap Up to $3.88
2 more Ohio counties to be subject of another opioid trial
2 more Ohio counties to be subject of another opioid trial
Beirne Wealth Consulting Services LLC Increases Stake in Mallinckrodt PLC (NYSE:MNK)
Mallinckrodt (NYSE:MNK) Rating Lowered to Strong Sell at ValuEngine
Analysts Estimate Mallinckrodt (MNK) to Report a Decline in Earnings: What to Look Out for
Aurinia Appoints Joe Miller as Chief Financial Officer
Mallinckrodt PLC Forecasted to Post FY2020 Earnings of $5.37 Per Share (NYSE:MNK)
Bank of New York Mellon Corp Decreases Holdings in Mallinckrodt PLC (NYSE:MNK)
Source: https://incomestatements.info
Category: Stock Reports